The Current Ratio as of December 2025 (TTM) for Mineralys Therapeutics, Inc. (MLYS) is 15.12

According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 15.12. This represents a change of -5.75% compared to the average of 16.04 of the last 4 quarters.

Mineralys Therapeutics, Inc. (MLYS) Historical Current Ratio (quarterly & annually)

How has MLYS Current Ratio performed in the past?

The mean historical Current Ratio of Mineralys Therapeutics, Inc. over the last ten years is 10.85. The current 15.12 Current Ratio has changed 13.83% with respect to the historical average. Over the past ten years (40 quarters), MLYS's Current Ratio was at its highest in in the June 2023 quarter at 43.42. The Current Ratio was at its lowest in in the March 2022 quarter at 0.

Mineralys Therapeutics, Inc. (MLYS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Mineralys Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mineralys Therapeutics, Inc. (MLYS) Average Current Ratio

How has MLYS Current Ratio performed in the past?

The current Current Ratio of Mineralys Therapeutics, Inc. (MLYS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Mineralys Therapeutics, Inc. (MLYS) Current Ratio vs. Peers

How is MLYS’s Current Ratio compared to its peers?

Mineralys Therapeutics, Inc.’s Current Ratio is greater than Cidara Therapeutics, Inc. (4.62), greater than Scholar Rock Holding Corporation (6.30), greater than IDEAYA Biosciences, Inc. (12.39), greater than Adaptive Biotechnologies Corporation (2.84), greater than Beam Therapeutics Inc. (6.02), greater than Catalyst Pharmaceuticals, Inc. (6.62), greater than Zai Lab Limited (3.12), greater than Apellis Pharmaceuticals, Inc. (3.54), greater than Agios Pharmaceuticals, Inc. (13.82), greater than Recursion Pharmaceuticals, Inc. (3.58),

Build a custom stock screener for Mineralys Therapeutics, Inc. (MLYS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mineralys Therapeutics, Inc. (MLYS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.